Shukra Pharmaceuticals Limited

SHUKRAPHAR6

INE551C01028

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:56 2024-07-01 EDT			5-day change	1st Jan Change
109.2 ^INR	-1.97%		-9.53%	+252.97%

05-29	Shukra Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2023- 24	CI
05-29	Shukra Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI

Shukra Pharmaceuticals Limited Approves Final Dividend for the Financial Year 2021-22

October 01, 2022 at 09:15 am

Shukra Pharmaceuticals Limited announced that at the AGM held on September 29, 2022, approved final dividend of 5% (INR 0.50 per equity of INR 10 each face value) for the financial year 2021-22.

Latest news about Shukra Pharmaceuticals Limited

Shukra Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2023- 24	05-29	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-29	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-12	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-11	CI
Shukra Pharmaceuticals Limited Announces the Resignation of Jivansingh Gangasingh Negi as Independent Director	23-10-06	CI
Shukra Pharmaceuticals Limited Announces Board Changes	23-08-16	CI
Shukra Pharmaceuticals Limited Announces Directorate Resignations	23-08-16	CI
Shukra Pharmaceuticals Limited Announces Executive Changes	23-08-12	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-12	CI
Shukra Pharmaceuticals Limited Announces Resignation of Ashvin Trivedi as Non- Executive Director, Effective August 12, 2023	23-08-07	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-29	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-29	CI
Shukra Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2023	23-05-29	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Shukra Pharmaceuticals Limited Announces Board Changes	22-11-12	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-12	CI
Shukra Pharmaceuticals Limited Approves Final Dividend for the Financial Year 2021-22	22-10-01	CI
Shukra Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2021-22	22-09-05	CI
Shukra Pharmaceuticals to Raise Up to $2.4 Million from Equity Offering	22-08-25	MT
Shukra Pharmaceuticals Limited Appoints Rai Kavoorguthu Konark as Additional Independent Director	22-08-25	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-06	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-05-28	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-28	CI
Shukra Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2021-22	22-05-28	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-12	CI

Chart Shukra Pharmaceuticals Limited

Duration

Period

More charts

Shukra Pharmaceuticals Limited is an India-based company, which is engaged primarily in the business of manufacturing and marketing of pharmaceutical products. The Company operates in two sectors: pharmaceutical and laboratory. The Company's manufacturing plant is situated in Rakanpur, Gandhinagar. The Company's product portfolio includes antibiotics (penicillin), anti-biotics (cephalosporin), anti-biotics, macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, anti-anthelmintic, sedative and tranquillizer, anti-depressant, anti-manic, anti-emetic, anti-ulcer, beta blockers, diuretics, analgesic, analgesic (NASID), muscle relaxants, anti-tuberculosis, vitamin products, anti-allergic, corticosteroids, hyper and hypoglycemic. The Company is engaged in manufacturing general formulations, such as tablets, capsules and small volume parenteral.

Sector

Pharmaceuticals

Calendar

2024-08-01 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SHUKRA PHARMACEUTICALS LIMITED	+252.97%	58.52M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.70%	43.77B
OTSUKA HOLDINGS CO., LTD.	+30.16%	22.83B
CIPLA LIMITED	+18.68%	14.34B
ZYDUS LIFESCIENCES LIMITED	+54.86%	12.96B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.72%	6.41B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.65%	5.69B
GEDEON RICHTER	+9.49%	4.75B